- Home
- AARD vs IPHA Comparison
AARD vs IPHA Comparison
Compare AARD & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- IPHA
- Stock Information
- Founded
- AARD 2017
- IPHA 1999
- Country
- AARD United States
- IPHA France
- Employees
- AARD N/A
- IPHA N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- AARD Health Care
- IPHA Health Care
- Exchange
- AARD Nasdaq
- IPHA Nasdaq
- Market Cap
- AARD 154.9M
- IPHA 160.1M
- IPO Year
- AARD 2025
- IPHA 2019
- Fundamental
- Price
- AARD $10.14
- IPHA $2.04
- Analyst Decision
- AARD Strong Buy
- IPHA Strong Buy
- Analyst Count
- AARD 4
- IPHA 1
- Target Price
- AARD $31.50
- IPHA $11.00
- AVG Volume (30 Days)
- AARD 69.4K
- IPHA 32.2K
- Earning Date
- AARD 01-01-0001
- IPHA 03-27-2025
- Dividend Yield
- AARD N/A
- IPHA N/A
- EPS Growth
- AARD N/A
- IPHA N/A
- EPS
- AARD N/A
- IPHA N/A
- Revenue
- AARD N/A
- IPHA $20,831,349.00
- Revenue This Year
- AARD N/A
- IPHA $209.83
- Revenue Next Year
- AARD N/A
- IPHA $83.96
- P/E Ratio
- AARD N/A
- IPHA N/A
- Revenue Growth
- AARD N/A
- IPHA N/A
- 52 Week Low
- AARD $4.88
- IPHA $1.29
- 52 Week High
- AARD $19.58
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- IPHA 45.40
- Support Level
- AARD N/A
- IPHA $2.22
- Resistance Level
- AARD N/A
- IPHA $2.56
- Average True Range (ATR)
- AARD 0.00
- IPHA 0.16
- MACD
- AARD 0.00
- IPHA 0.00
- Stochastic Oscillator
- AARD 0.00
- IPHA 11.86
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.